

DYNAVAX TECHNOLOGIES CORP
 Form 3
 July 11, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Janssen Robert
 (Last) (First) (Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)
 07/09/2013

3. Issuer Name and Ticker or Trading Symbol

DYNAVAX TECHNOLOGIES CORP [DVAX]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

Director 10% Owner
 Officer Other
 (give title below) (specify below)
 Chief Medical Officer and VP

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

C/O DYNAVAX
 TECHNOLOGIES,Â 2929
 SEVENTH STREET, SUITE 100
 (Street)

BERKELEY,Â CAÂ 94710
 (City) (State) (Zip)

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|------------------------------------|--|---|--|
| Common Stock | 25,481 | D | Â |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative | 5. Ownership Form of Derivative Security: | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---|---|--|---|---|--|
|---|---|--|---|---|--|

Edgar Filing: DYNAVAX TECHNOLOGIES CORP - Form 3

| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | Security | Direct (D) or Indirect (I) (Instr. 5) | |
|-----------------------|------------------|-----------------|--------------|----------------------------|----------|---------------------------------------|---|
| Option (Right to Buy) | Â (1) | 04/06/2020 | Common Stock | 60,000 | \$ 1.36 | D | Â |
| Option (Right to Buy) | Â (2) | 01/05/2021 | Common Stock | 22,500 | \$ 3.14 | D | Â |
| Option (Right to Buy) | Â (3) | 01/31/2022 | Common Stock | 25,000 | \$ 3.68 | D | Â |
| Option (Right to Buy) | Â (3) | 10/30/2022 | Common Stock | 150,000 | \$ 4.14 | D | Â |
| Restricted Stock Unit | Â (4) | 03/08/2022 | Common Stock | 20,000 | \$ 4.22 | D | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|--------------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Janssen Robert C/O DYNAVAX TECHNOLOGIES 2929 SEVENTH STREET, SUITE 100 BERKELEY, CA 94710 | Â | Â | Â Chief Medical Officer and VP | Â |

Signatures

Robert Janssen, M.D., by /s/ Jennifer Lew,
Attorney-in Fact

07/11/2013

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This option grant vests in equal annual installments over four years on the anniversary of the grant date.

This option grant shall vest over three (3) years with one third (1/3) of the Shares subject to the Option vesting twelve months after the

(2) Vesting Commencement Date, and one thirty-sixth (1/36) of the Shares subject to the Option vesting on the last day of each month thereafter.

This option grant shall vest over four (4) years with one fourth (1/4) of the Shares subject to the Option vesting twelve months after the

(3) Vesting Commencement Date, and one forty-eighth (1/48) of the Shares subject to the Option vesting on the last day of each month thereafter.

(4) These restricted stock units shall vest upon achievement of certain performance conditions.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.